Allianz Asset Management GmbH Invests $307,000 in MEDIFAST INC $MED

Allianz Asset Management GmbH acquired a new position in MEDIFAST INC (NYSE:MED) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 21,842 shares of the specialty retailer’s stock, valued at approximately $307,000. Allianz Asset Management GmbH owned about 0.20% of MEDIFAST as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in MED. Values First Advisors Inc. lifted its holdings in shares of MEDIFAST by 3.8% in the 1st quarter. Values First Advisors Inc. now owns 64,228 shares of the specialty retailer’s stock worth $869,000 after acquiring an additional 2,340 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in MEDIFAST during the 1st quarter worth approximately $933,000. Charles Schwab Investment Management Inc. increased its stake in MEDIFAST by 132.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 265,572 shares of the specialty retailer’s stock worth $3,580,000 after buying an additional 151,434 shares during the period. Benjamin Edwards Inc. increased its stake in MEDIFAST by 75.0% during the 1st quarter. Benjamin Edwards Inc. now owns 24,419 shares of the specialty retailer’s stock worth $329,000 after buying an additional 10,469 shares during the period. Finally, Nuveen LLC purchased a new stake in MEDIFAST during the 1st quarter worth approximately $407,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

MEDIFAST Price Performance

Shares of NYSE:MED opened at $12.72 on Wednesday. The stock has a market cap of $139.80 million, a P/E ratio of 39.75 and a beta of 0.85. The firm has a fifty day moving average price of $13.67 and a 200 day moving average price of $13.54. MEDIFAST INC has a 1-year low of $11.57 and a 1-year high of $21.98.

MEDIFAST (NYSE:MED) last released its earnings results on Monday, August 4th. The specialty retailer reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.26. MEDIFAST had a net margin of 0.76% and a return on equity of 2.00%. The company had revenue of $105.56 million during the quarter, compared to analysts’ expectations of $96.10 million. MEDIFAST has set its Q3 2025 guidance at -0.600-0.00 EPS. Sell-side analysts expect that MEDIFAST INC will post 0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of MEDIFAST in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $16.50.

MEDIFAST Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.